These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 8847836)
1. Inhibitory effects of the new anti-platelet agent KBT-3022 and its metabolite on rabbit neutrophil function in vitro. Yokota K; Yamamoto N; Obata Y; Oda M Jpn J Pharmacol; 1996 Apr; 70(4):291-302. PubMed ID: 8847836 [TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of KBT-3022, a new anti-platelet agent, on infiltration of polymorphonuclear leukocytes induced by leukotriene B4 or formyl-methionyl-leucyl-phenylalanine in mice. Yokota K; Yamamoto N; Obata Y; Oda M Jpn J Pharmacol; 1995 Jul; 68(3):353-7. PubMed ID: 7474560 [TBL] [Abstract][Full Text] [Related]
3. The mechanism of action of KBT-3022, a new antiplatelet agent. Matsuo K; Yokota K; Yamashita A; Oda M Gen Pharmacol; 1997 Feb; 28(2):229-35. PubMed ID: 9013200 [TBL] [Abstract][Full Text] [Related]
4. Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022. Shimazawa M; Takiguchi Y; Umemura K; Kondo K; Nakashima M Eur J Pharmacol; 1997 Jun; 328(2-3):183-9. PubMed ID: 9218700 [TBL] [Abstract][Full Text] [Related]
5. Effect of KBT-3022, a new cyclooxygenase inhibitor, on experimental brain edema in vitro and in vivo. Yamamoto N; Yokota K; Yamashita A; Oda M Eur J Pharmacol; 1996 Feb; 297(3):225-31. PubMed ID: 8666054 [TBL] [Abstract][Full Text] [Related]
6. Effect of KBT-3022, a new diphenylthiazole derivative, on platelet functions. Yokota K; Yamamoto N; Morimoto Y; Yamashita A; Oda M J Pharm Pharmacol; 1995 Sep; 47(9):768-74. PubMed ID: 8583391 [TBL] [Abstract][Full Text] [Related]
7. Anti-thrombotic activity of KBT-3022 in experimental models of thrombosis. Yokota K; Yamashita A; Oda M Jpn J Pharmacol; 1995 Jun; 68(2):201-6. PubMed ID: 7563977 [TBL] [Abstract][Full Text] [Related]
8. Effect of a Korean traditional formulation, Hwaotang, on superoxide generation in human neutrophils, platelet aggregation in human blood, and nitric oxide, prostaglandin E2 production and paw oedema induced by carrageenan in mice. Park WH; Park SY; Kim HM; Kim CH Immunopharmacol Immunotoxicol; 2004 Feb; 26(1):53-73. PubMed ID: 15106732 [TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharide modulates receptors for leukotriene B4, C5a, and formyl-methionyl-leucyl-phenylalanine on rabbit polymorphonuclear leukocytes. Goldman DW; Enkel H; Gifford LA; Chenoweth DE; Rosenbaum JT J Immunol; 1986 Sep; 137(6):1971-6. PubMed ID: 3018083 [TBL] [Abstract][Full Text] [Related]
10. [Determination of the main metabolite (desethyl KBT-3022) of a new antiplatelet agent, KBT-3022 in plasma by gas chromatography]. Nakada Y; Shimada H; Awata N Yakugaku Zasshi; 1992 Jun; 112(6):414-7. PubMed ID: 1432594 [TBL] [Abstract][Full Text] [Related]
11. NPC 15669-modulated human polymorphonuclear neutrophil functional responsiveness: effects on receptor-coupled signal transduction. Smith RJ; Justen JM; Bleasdale JE; Sly LM Br J Pharmacol; 1995 Apr; 114(8):1694-702. PubMed ID: 7599938 [TBL] [Abstract][Full Text] [Related]
12. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils. Koike H; Imanishi N; Natsume Y; Morooka S Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770 [TBL] [Abstract][Full Text] [Related]
13. Cilostazol suppresses adhesion of human neutrophils to HUVECs stimulated by FMLP and its mechanisms. Yang Y; Luo J; Kazumura K; Takeuchi K; Inui N; Hayashi H; Ohashi K; Watanabe H Life Sci; 2006 Jul; 79(7):629-36. PubMed ID: 16564549 [TBL] [Abstract][Full Text] [Related]
14. Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982. Jackson WT; Boyd RJ; Froelich LL; Mallett BE; Gapinski DM J Pharmacol Exp Ther; 1992 Dec; 263(3):1009-14. PubMed ID: 1335049 [TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of human neutrophil activation by cyclosporins A, D, and H. Cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation. Wenzel-Seifert K; Grünbaum L; Seifert R J Immunol; 1991 Sep; 147(6):1940-6. PubMed ID: 1653806 [TBL] [Abstract][Full Text] [Related]
16. Pro-inflammatory and anti-inflammatory effects of the stable prostaglandin D2 analogue, ZK 118.182. Pons F; Williams TJ; Kirk SA; McDonald F; Rossi AG Eur J Pharmacol; 1994 Aug; 261(3):237-47. PubMed ID: 7813544 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of some human neutrophil functions by the cyclooxygenase inhibitor ketorolac tromethamine. Hyers TM; Tricomi SM; Liao JJ J Leukoc Biol; 1992 May; 51(5):490-5. PubMed ID: 1318350 [TBL] [Abstract][Full Text] [Related]
18. SC-41930: an inhibitor of leukotriene B4-stimulated human neutrophil functions. Tsai BS; Villani-Price D; Keith RH; Zemaitis JM; Bauer RF; Leonard R; Djuric SW; Shone RL Prostaglandins; 1989 Dec; 38(6):655-74. PubMed ID: 2561214 [TBL] [Abstract][Full Text] [Related]
19. ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions. Kishikawa K; Tateishi N; Maruyama T; Seo R; Toda M; Miyamoto T Prostaglandins; 1992 Oct; 44(4):261-75. PubMed ID: 1332129 [TBL] [Abstract][Full Text] [Related]
20. Human neutrophil Fc gamma RIIIB and formyl peptide receptors are functionally linked during formyl-methionyl-leucyl-phenylalanine-induced chemotaxis. Kew RR; Grimaldi CM; Furie MB; Fleit HB J Immunol; 1992 Aug; 149(3):989-97. PubMed ID: 1321856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]